Figure 3
Exposure of iBREC to Beovu but not to Lucentis changed plasma membrane localization of TJ-protein claudin-1. A confluent monolayer of iBREC was treated with Beovu or Lucentis for five days before cells were fixated, and claudin-1 (upper panel), claudin-5 (middle panel) or VEcadherin (lower panel; all in red) were visualized by immunofluorescence stainings with specific antibodies. Lucentis did not markedly change the presence of any of the investigated proteins at the plasma membrane. Whereas subcellular localization of claudin-5 or VEcadherin remained largely unchanged also in the presence of Beovu, the staining specific for claudin-1 was weaker after exposure of the cells to the VEGF-A antagonist.
